Header Logo

Connection

JOSEPH JANKOVIC to Clinical Trials as Topic

Back to Details
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Clinical Trials as Topic.
JOSEPH JANKOVIC
Connection Strength
1.428
Clinical Trials as Topic
  1. How should future clinical trials be designed in the search for disease-modifying therapies for Parkinson's disease? Expert Rev Neurother. 2023 02; 23(2):107-122.
    View in: PubMed
    Score: 0.565
  2. Exploring the role of botulinum toxin in critical care. Expert Rev Neurother. 2021 08; 21(8):881-894.
    View in: PubMed
    Score: 0.127
  3. Immunologic treatment of Parkinson's disease. Immunotherapy. 2018 02; 10(2):81-84.
    View in: PubMed
    Score: 0.099
  4. Designing clinical trials for dystonia. Neurotherapeutics. 2014 Jan; 11(1):117-27.
    View in: PubMed
    Score: 0.075
  5. Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE). BMC Neurol. 2011 Nov 04; 11:140.
    View in: PubMed
    Score: 0.065
  6. Epidemiology and management of essential tremor in children. Paediatr Drugs. 2009; 11(5):293-307.
    View in: PubMed
    Score: 0.053
  7. Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord. 2007 Dec; 22(16):2371-7.
    View in: PubMed
    Score: 0.049
  8. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease. Expert Rev Neurother. 2007 Jun; 7(6):637-47.
    View in: PubMed
    Score: 0.047
  9. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother. 2006 Jan; 6(1):7-17.
    View in: PubMed
    Score: 0.043
  10. Treatment of cervical dystonia with botulinum toxin. Mov Disord. 2004 Mar; 19 Suppl 8:S109-15.
    View in: PubMed
    Score: 0.038
  11. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology. 2004 Jan 27; 62(2):343; author reply 343-4.
    View in: PubMed
    Score: 0.038
  12. Dopamine agonists in Parkinson's disease. Expert Opin Investig Drugs. 2003 Nov; 12(11):1803-20.
    View in: PubMed
    Score: 0.037
  13. Botulinum toxin for the treatment of cervical dystonia. Expert Opin Pharmacother. 2001 Dec; 2(12):1985-94.
    View in: PubMed
    Score: 0.032
  14. Choosing dopamine agonists in Parkinson's disease. Clin Neuropharmacol. 2001 Sep-Oct; 24(5):247-53.
    View in: PubMed
    Score: 0.032
  15. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging. 2001; 18(6):389-96.
    View in: PubMed
    Score: 0.030
  16. Treatable inherited rare movement disorders. Mov Disord. 2018 01; 33(1):21-35.
    View in: PubMed
    Score: 0.024
  17. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997 Feb; 48(2):358-62.
    View in: PubMed
    Score: 0.023
  18. Emerging therapies for Parkinson's disease. Curr Opin Neurol. 2012 Aug; 25(4):448-59.
    View in: PubMed
    Score: 0.017
  19. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology. 1988 Mar; 38(3):391-4.
    View in: PubMed
    Score: 0.012
  20. Blepharospasm and oromandibular-laryngeal-cervical dystonia: a controlled trial of botulinum A toxin therapy. Adv Neurol. 1988; 50:583-91.
    View in: PubMed
    Score: 0.012
  21. Benefits and risks of pharmacological treatments for essential tremor. Drug Saf. 2003; 26(7):461-81.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.